Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy

January 6, 2026 updated by: Louis Tong, Singapore National Eye Centre
The purpose of this research study is to understand the mechanism of action of low level light therapy and also potentially yield markers associated with good treatment response. Low-level light therapy is light-based treatment delivered through advance eye-light device. This therapy uses light energy to provide energy to the meibomian gland cells to slow down age-ing, improve tear stability and reduce inflammation.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patient undergoing low level light therapy that met the study inclusion and exclusion

Description

Inclusion Criteria:

  1. Must be eligible for, and have consented for low level light therapy
  2. Must not have presented to the clinic for an acute eye problem such as visual loss or painful eye
  3. Ability to give informed consent.
  4. Age more or equals to 21 years old.

Exclusion Criteria:

  1. Patients who are unable to or decline to give consent.
  2. Age less than 21 years old.
  3. Patients who presented to the clinic for an acute eye problem such as visual loss or painful eye.

  4. Patients not suitable for low level lighttherapy:

    • Pregnant
    • Fitted with pacemakers, metal, electrical, acoustic prosthetics
    • Epilepsy, cardiac rhythm or frequency disorders
    • Fever, thrombophlebitis or acute phlebitis of the legs, large-sized varicose veins, or venous surgery within 2 months
    • Uncontrolled hypertension or severe diabetes
    • Open wounds on eyelid or skin
    • Evolving cancer or hepatitis
    • Blood anticoagulant or coagulation defect

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients undergoing low level light therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparing tear proteomics profile in dry eye disease pre-and post-treatment with low level light therapy
Time Frame: Baseline visit and Post Baseline visit 3 months (+3 weeks).
Aim 1: Tear proteomic profile of MGD patients with DED pre- and post-treatment with LLLT will be profiled Aim 2: Baseline tear cytokine levels will be measured using the novel Olink 500-plex technology in DED patients with MGD undergoing LLLT
Baseline visit and Post Baseline visit 3 months (+3 weeks).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Singapore National Eye Centre

Investigators

  • Principal Investigator: Louis Tong, PhD, Singapore Eye Research Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 5, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

December 21, 2025

First Submitted That Met QC Criteria

January 6, 2026

First Posted (Actual)

January 9, 2026

Study Record Updates

Last Update Posted (Actual)

January 9, 2026

Last Update Submitted That Met QC Criteria

January 6, 2026

Last Verified

November 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025-0870 (Other Identifier: Singhealth CIRB)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dry Eye

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe